Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05848232
Other study ID # CP-009
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date June 2024
Est. completion date February 2025

Study information

Verified date November 2023
Source ReFlow Medical, Inc.
Contact Sara Finton
Phone 616-633-9178
Email sfinton@reflowmedical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of the coraFlex, coraForce, and coraCross catheters for crossing chronic total occlusions of the coronary arteries. The study will compare the rate of procedure success to success rates from previous trials. Participants will undergo percutaneous coronary intervention (PCI) for a chronic total occlusion and be followed for 30 days post-procedure.


Description:

The primary objective of this prospective, multicenter, single arm clinical study is to compare the rate of procedure success of the coraCross, coraForce, and coraFlex catheters in facilitating guidewire placement beyond coronary chronic total occlusions to a pre-defined performance goal based on literature. The study population will consist of those 18 years or older with symptomatic ischemic heart disease, undergoing clinically indicated percutaneous recanalization of an occlusive coronary lesion, and meeting all other eligibility criteria. Measures will be assessed through 30 days post-intervention.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date February 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pre-Procedure Inclusion Criteria: 1. Subject willing and able to provide informed consent and able to comply with the study protocol and follow up. 2. Male or non-pregnant female =18 years of age at time of consent. 3. Subjects experiencing clinical symptoms suggestive of ischemic heart disease or has evidence of myocardial ischemia attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization. 4. Subject is a candidate for PTCA, stenting, and emergency CABG. - Angiographic Inclusion Criteria: 1. A minimum of one de novo lesion with at least one target segment in a native coronary vessel meeting CTO criteria {defined as TIMI grade 0 flow} and estimated to be > 3 months duration by clinical history and/or comparison with a prior angiogram or electrocardiogram. Exclusion Criteria: - Pre-procedure Exclusion Criteria: 1. Subject unwilling or unable to comply with the protocol or follow-up requirements, in the opinion of the investigator. 2. Subject life expectancy less than one year, in the opinion of the investigator. 3. Subject is pregnant or planning to become pregnant during the course of the trial. 4. Evidence of MI within 72 hours prior to the index procedure. 5. History of stroke or transient ischemic attack within 6 months prior to the index procedure. 6. Prior coronary interventional procedure (including coronary artery bypass graft surgery) of any kind within 30 days of the index procedure. 7. Inability to tolerate DAPT with aspirin plus a P2Y12 inhibitor. 8. Known allergies or sensitivities to heparin, antiplatelet drugs, or other anticoagulant therapies, which could not be substituted, including history of major bleeding event in the last 6 months. 9. Allergy or sensitivity to contrast media that cannot be adequately pre-treated prior to the index procedure. 10. Subjects with known history of clinically significant abnormal laboratory findings =30 days prior to enrollment including: 1. Neutropenia (<1000 neutrophils/mm3) 2. Thrombocytopenia (<100,000 platelets/mm3) 3. AST, ALT, ALP, or bilirubin > 1.5 times ULN 4. Serum creatinine > 2.0 mg/dL 11. Subject has signs/symptoms of systemic infection/sepsis (temperature = 38.00 Celsius and WBC =12,000 cells/µL). If subject has localized infection or infection is adequately treated and controlled, per investigator discretion, patient may be enrolled. 12. Evidence of current clinical instability including: 1. Sustained systolic blood pressure <100 mmHg or cardiogenic shock 2. Acute pulmonary edema or severe congestive heart failure (NYHA class IV) 3. Known or suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade 4. Known or suspected dissecting aortic aneurysm 5. Hemodynamically significant valvular heart disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease. 6. Requires mechanical circulatory support (e.g., Impella) during index procedure 13. Subject is currently enrolled in another investigational device or drug trial that interferes with the study endpoints. 14. Any concurrent, medical, psychological, or social condition which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator. - Angiographic Exclusion Criteria: 1. Target lesion is located within a stent (in-stent occlusion). 2. Target vessel has other lesions proximal to the total occlusion with >75% stenosis (based on visual estimate) unless there is planned stenting of the proximal lesion as well. 3. Angiography demonstrates extensive lesion related thrombus (TIMI thrombus grade 3 or 4). 4. Fractured stents in the target vessel.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
coraFlex Catheter
The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
coraForce Catheter
The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
coraCross Catheter
The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.

Locations

Country Name City State
United States University of Washington Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
ReFlow Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedure success defined as technical success and the absence of in-hospital Major Adverse Cardiovascular Events (MACE) Technical success is defined as angiographic confirmation of chronic total occlusion crossing with guidewire placement, facilitated by one or more of the Cora Catheters, in the target vessel true lumen either distal or proximal to the occlusion, depending on the route of access.
MACE includes cardiac death, myocardial infarction {Q-wave or non-Q-wave, with CK-MB >3 times upper limit of normal}, and target lesion revascularization
Through hospital discharge or 24 hours post-procedure (whichever comes first)
See also
  Status Clinical Trial Phase
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Completed NCT00987610 - Guidewire for Chronic Total Occlusion Phase 4
Completed NCT02533128 - Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery N/A
Completed NCT04246125 - Patient Skin Dose in Interventional Radiology
Completed NCT03717675 - Supplemental Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter N/A
Recruiting NCT03588481 - IRIS- DESyne X2 in the IRIS-DES Registry
Recruiting NCT05089864 - STAR and Deferred Stenting Study N/A
Not yet recruiting NCT03719014 - Cohort B of the Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter N/A
Not yet recruiting NCT02963584 - Decision Aid in Chronic Total Occlusion (CTO) Patients N/A
Completed NCT00793221 - Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent Phase 3
Completed NCT04281212 - Observational Study Evaluating the Management of Chronic Coronary Occlusions In France
Not yet recruiting NCT04562142 - A Novel Non-Invasive Acoustic Diagnostic for the Diagnosis of Coronary Artery Disease The CAD-det Validation Study N/A
Enrolling by invitation NCT02931331 - Coronary Revascularization Assessed by Stress PET N/A
Terminated NCT02683356 - Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds N/A
Completed NCT00657436 - Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement N/A
Terminated NCT03993522 - Exercise in Patients With a Total Coronary Occlusion N/A
Not yet recruiting NCT03159650 - Comparative Study Between Intravascular Ultrasonography Guided and Angiography-guided Recanalization of Coronary Chronic Total Occlusions N/A
Recruiting NCT02325869 - Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS) N/A
Completed NCT00640068 - Advanced Cardiovascular Imaging Consortium N/A
Completed NCT01759290 - ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients. N/A